Natco Pharma [NATCOPHARM] vs Dr. Lal PathLabs [LALPATHLAB] Detailed Stock Comparison
Natco Pharma
NSE
Loading...
Dr. Lal PathLabs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Natco Pharma wins in 15 metrics, Dr. Lal PathLabs wins in 5 metrics, with 0 ties. Natco Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Natco Pharma | Dr. Lal PathLabs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 9.33 | 54.95 | Natco Pharma |
| Price-to-Book Ratio | 2.08 | 12.95 | Natco Pharma |
| Debt-to-Equity Ratio | 3.67 | 7.14 | Natco Pharma |
| PEG Ratio | -0.33 | 2.27 | Natco Pharma |
| EV/EBITDA | 6.93 | 39.93 | Natco Pharma |
| Profit Margin (TTM) | 38.62% | 20.29% | Natco Pharma |
| Operating Margin (TTM) | 38.63% | 23.54% | Natco Pharma |
| EBITDA Margin (TTM) | 38.63% | 23.54% | Natco Pharma |
| Return on Equity | 24.77% | 22.08% | Natco Pharma |
| Return on Assets (TTM) | 21.85% | 17.93% | Natco Pharma |
| Free Cash Flow (TTM) | $11.85B | $5.15B | Natco Pharma |
| Dividend Yield | 0.92% | 0.93% | Dr. Lal PathLabs |
| 1-Year Return | -43.37% | 2.15% | Dr. Lal PathLabs |
| Price-to-Sales Ratio (TTM) | 3.60 | 11.13 | Natco Pharma |
| Enterprise Value | $135.92B | $271.63B | Dr. Lal PathLabs |
| EV/Revenue Ratio | 3.09 | 10.74 | Natco Pharma |
| Gross Profit Margin (TTM) | 82.47% | 66.99% | Natco Pharma |
| Revenue per Share (TTM) | $245 | $303 | Dr. Lal PathLabs |
| Earnings per Share (Diluted) | $94.78 | $61.42 | Natco Pharma |
| Beta (Stock Volatility) | 0.19 | 0.08 | Dr. Lal PathLabs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Natco Pharma vs Dr. Lal PathLabs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Natco Pharma | -0.86% | 0.91% | -13.03% | 0.59% | 7.21% | -36.85% |
| Dr. Lal PathLabs | -0.44% | -1.57% | 12.35% | 19.67% | 30.32% | 10.54% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Natco Pharma | -43.37% | 41.34% | 10.28% | 94.06% | 1,592.79% | 3,459.70% |
| Dr. Lal PathLabs | 2.15% | 28.00% | 83.35% | 276.64% | 276.64% | 276.64% |
Performance & Financial Health Analysis: Natco Pharma vs Dr. Lal PathLabs
| Metric | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹158.37B | ₹281.63B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 532,696 | 104,866 |
| 90 Day Avg. Volume | 958,882 | 126,059 |
| Last Close | ₹874.85 | ₹3,359.90 |
| 52 Week Range | ₹726.80 - ₹1,639.00 | ₹2,293.55 - ₹3,653.95 |
| % from 52W High | -46.62% | -8.05% |
| All-Time High | ₹1,639.00 (Sep 09, 2024) | ₹4,245.50 (Sep 13, 2021) |
| % from All-Time High | -46.62% | -20.86% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.03% | 0.11% |
| Quarterly Earnings Growth | -0.28% | 0.24% |
| Financial Health | ||
| Profit Margin (TTM) | 0.39% | 0.20% |
| Operating Margin (TTM) | 0.39% | 0.24% |
| Return on Equity (TTM) | 0.25% | 0.22% |
| Debt to Equity (MRQ) | 3.67 | 7.14 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹424.69 | ₹260.62 |
| Cash per Share (MRQ) | ₹139.41 | ₹139.63 |
| Operating Cash Flow (TTM) | ₹19.26B | ₹4.66B |
| Levered Free Cash Flow (TTM) | ₹18.85B | ₹4.87B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.92% | 0.93% |
| Last 12-Month Dividend | ₹8.00 | ₹30.00 |
Valuation & Enterprise Metrics Analysis: Natco Pharma vs Dr. Lal PathLabs
| Metric | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 9.33 | 54.95 |
| Forward P/E | 21.42 | 114.87 |
| PEG Ratio | -0.33 | 2.27 |
| Price to Sales (TTM) | 3.60 | 11.13 |
| Price to Book (MRQ) | 2.08 | 12.95 |
| Market Capitalization | ||
| Market Capitalization | ₹158.37B | ₹281.63B |
| Enterprise Value | ₹135.92B | ₹271.63B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.09 | 10.74 |
| Enterprise to EBITDA | 6.93 | 39.93 |
| Risk & Other Metrics | ||
| Beta | 0.19 | 0.08 |
| Book Value per Share (MRQ) | ₹424.69 | ₹260.62 |
Financial Statements Comparison: Natco Pharma vs Dr. Lal PathLabs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Revenue/Sales | ₹13.29B | ₹6.70B |
| Cost of Goods Sold | ₹2.33B | ₹2.21B |
| Gross Profit | ₹10.96B | ₹4.49B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹5.13B | ₹1.58B |
| EBITDA | ₹6.33B | ₹2.20B |
| Pre-Tax Income | ₹5.72B | ₹1.81B |
| Income Tax | ₹916.00M | ₹471.00M |
| Net Income (Profit) | ₹4.80B | ₹1.34B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Cash & Equivalents | ₹1.20B | ₹2.93B |
| Total Current Assets | ₹52.70B | ₹13.64B |
| Total Current Liabilities | ₹9.44B | ₹4.02B |
| Long-Term Debt | ₹46.00M | ₹1.03B |
| Total Shareholders Equity | ₹76.12B | ₹22.06B |
| Retained Earnings | N/A | ₹18.60B |
| Property, Plant & Equipment | ₹24.32B | ₹3.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 532,696 | 104,866 |
| Average Daily Volume (90 Day) | 958,882 | 126,059 |
| Shares Outstanding | 179.11M | 83.37M |
| Float Shares | 83.13M | 37.19M |
| % Held by Insiders | 0.51% | 0.57% |
| % Held by Institutions | 0.13% | 0.32% |
Dividend Analysis & Yield Comparison: Natco Pharma vs Dr. Lal PathLabs
| Metric | NATCOPHARM | LALPATHLAB |
|---|---|---|
| Last 12-Month Dividend | ₹8.00 | ₹30.00 |
| Last 12-Month Dividend Yield | 0.92% | 0.93% |
| 3-Year Avg Annual Dividend | ₹6.50 | ₹20.00 |
| 3-Year Avg Dividend Yield | 0.24% | 0.28% |
| 3-Year Total Dividends | ₹19.50 | ₹60.00 |
| Ex-Dividend Date | Aug 19, 2025 | Aug 06, 2025 |